Testing effectiveness (Phase 2)Active Not RecruitingNCT04756401
What this trial is testing
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Academic and Community Cancer Research United 8